期刊文献+

应用ROC曲线评价神经元特异性烯醇化酶对肺癌诊断的意义 被引量:6

Evaluation of the significance of NSE in diagnosis of lung cancer by ROC curve analysis
下载PDF
导出
摘要 目的:应用受试者工作特征曲线(Receiver operating characteristic,ROC)曲线分析评价肿瘤标志物神经元特异性烯醇化酶(Neuron-specific enolase,NSE)对肺癌的诊断价值。方法:利用回顾性分析方法,分析了123例肺癌患者及109例肺部良性疾病患者的血清NSE水平,采用ROC评价NSE对肺癌的诊断效能。结果:①不同病理分型的肺癌患者组血清NSE水平均明显高于肺部良性疾病患者组(P<0.01);②通过ROC曲线分析,NSE对肺癌诊断的敏感度、特异度、曲线下面积分别为64.2%6、7.9%、0.73%;③NSE与CEA、CYFRA21-1联合检测分析对肺癌的诊断敏感度可达93.5%。结论:NSE单一指标检测对肺癌辅助诊断有一定的价值,其与CEA、CYFRA21-1联合检测可增加对肺癌诊断的敏感性。 Objective:To evaluate the significance of neuron-specific enolase(NSE)in diagnosis of lung cancer by ROC curve analysis.Methods:The NSE levels in serum of 123 lung cancer patients and 109 patients with benign lung diseases were analyzed retrospectively and the diagnostic performance of NSE in lung cancer was evaluated with Receiver operating characteristic curve(ROC).Results:① Serum levels of NSE in the three pathological types of lung cancer patients were significantly higher than those in benign lung disease group(P0.01);② The sensitivity,specificity,and area under ROC curve of serum NSE levels in lung cancer patients were respectively 64.2%,67.9% and 0.73%,by ROC curve analysis;③Combined determination of NSE,CEA and CYFRA21-1 had sensitivity of 93.5% for lung cancer diagnosis.Conclusion:The determination of NSE for diagnosis of lung cancer is of value,and the combined determination of NSE,CEA and CYFRA21-1 can increase sensitivity in diagnosis of lung cancer.
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2011年第2期198-200,共3页 Journal of Chongqing Medical University
基金 重庆市教育委员会项目资助(编号:KJ100310)
关键词 神经元特异性烯醇化酶 肺癌 肿瘤标志物 ROC曲线 neuron-specific enolase lung cancer tumor marker ROC curve
  • 相关文献

参考文献9

  • 1赵振,顾玉海.神经元特异性烯醇化酶在小细胞肺癌中的价值研究[J].临床肺科杂志,2009,14(3):350-350. 被引量:13
  • 2Steak M, Oenings A, Eymanne E, et al.Develepment of a new automated enzyme immunoassay for the determination of neuro-speciflc enolapse [J].Antieaneer Res, 1999,19(4A) : 2759-2762.
  • 3张丽君,齐为民.神经元特异性烯醇化酶与小细胞肺癌研究进展[J].国外医学(肿瘤学分册),2001,28(2):136-138. 被引量:21
  • 4Pujol J L,Quantin X,Jacot W,et al.Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer [J]. Lung Cancer, 2003,39(2) : 131-138.
  • 5Ruibal A,Nuhez M I,Rodriguez J,et al.Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung [J].Biol Markers, 2003,18 (3) : 188-194.
  • 6张青云,徐建军,王雅明.人神经元特异性烯醇化酶在肿瘤细胞系中的表达检测及意义[J].中华检验医学杂志,2005,28(7):728-731. 被引量:12
  • 7He P,Naka T,Serada S,et al.Proteomics-based identification ofalpha-enolase as a tumor antigen in non-small lung cancer[J].Cancer Sci, 2007,98(8) : 1234-1240.
  • 8Zych J,Sztunnowicz M, Sakowicz A,et al.Neuron-specific eno-lase (NSE) serum level as a prognostic factor in non small cell lung cancer[J]. Preumonol Alergol Pol, 2002,70 (5-6) : 278-283.
  • 9Muraki M,Tohda Y,Lwanga T,et al.Assessment of serum CYFR A21 - 1 in lung caneer[J].Cancer, 1996,77 ( 7 ) : 1274-1277.

二级参考文献13

共引文献41

同被引文献44

  • 1王琦,任秀宝,蒋敬庭.肺癌免疫细胞治疗临床转化的研究进展[J].中国肿瘤生物治疗杂志,2015,22(3):375-380. 被引量:11
  • 2Fallahpour M, Hafizi A, Fouladgar A, et al. Neonatal atypical hemo- lytic uremic syndrome may cause prenatal asphyxia [ J ]. Arch Iran Med, 2012, 15 (11): 729-730.
  • 3Dereksson K, Kjartansson S, Hjartardottir H, et al. Ichthyosis prema- turity syndrome with separation of fetal membranes and neonatal asphyxia [J]. BMJ Case Rep, 2012 -03 -27.
  • 4Bettington CS, Tripcony L, Bryant G. A retrospective a- nalysis of survival outcomes for two different radiothera py fractionation schedules given in the same overall time for limited stage small cell lung cancer[J]. J Med Imaging Radiat Oncol,2013,57(1) : 105-112.
  • 5Alevizakos M, Kaltsas S, Syrigos KN. The VEGF path way in lung cancerFJ~. Cancer Chemother Pharmacol, 2013,72(6) :1169-1181.
  • 6Tanaka F,Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer[J~. Cancer Res,2002,62(23) :7124-7129.
  • 7Yamaguehi Y, Ohshita A, Kawabuchi Y, et al. Adoptive immunotherapy of cancer using activatedautologous lymphocytes-current status andnew strategies EJ~. Hum Ce11,2003,16(4) :183-189.
  • 8Colaco RJ, Huh S, Nichols RC, et al. Dosimetric rationale and early experience at UFPT1 of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer [J]. Aeta Oncol,2013,52(3) :506-513.
  • 9Andersen M,Kristjansen PE, Hansen HH. Seconded line chemotherapy in small cell lung cancer[J]. Cancer.Treat Rev, 1990,17(4) :427-436.
  • 10Kelly K. New chemotherapy agents for small cell lung cancer[J]. Chest,2000,117(4 Suppl 1) : 156S-162S.

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部